Related Experiment Video
Updated: May 9, 2026
10:47
Rapid Detection of Neurodevelopmental Phenotypes in Human Neural Precursor Cells (NPCs)
Published on: March 2, 2018
Developing new pharmacotherapies for autism.
1Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, London, UK.
Journal of Internal Medicine
|July 20, 2013
Summary
Developing targeted autism spectrum disorder (ASD) pharmacotherapies is challenging due to ASD's complexity. New insights into genetics and neurobiology offer opportunities for personalized treatments and a strategic framework for drug development.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Autism spectrum disorder (ASD) presents significant challenges for pharmacotherapy development due to its complex genetic basis, diverse neurobiological characteristics, and varied symptom presentation.
- Emerging research offers new avenues for developing targeted and individualized pharmacological interventions for ASD.
- Understanding the genetic and neurobiological underpinnings of ASD is crucial for advancing treatment strategies.
Purpose of the Study:
- To review current insights into the etiology and neurobiology of ASD, focusing on genetic variants affecting synaptic function and neurobiological differences.
- To propose a strategic framework for developing targeted pharmacotherapies for ASD, integrating research findings into clinical applications.
- To introduce the European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS) Initiative as a platform for translational research in ASD.
Main Methods:
- Review of genetic variants influencing synaptic structure and function in ASD.
- Analysis of neuroanatomical, chemical, and connectivity differences in the brains of individuals with ASD.
- Development of a strategic framework for translating research into clinical applications, including the use of animal models and cellular assays.
- Presentation of the EU-AIMS Initiative, a collaborative platform for translational research.
Main Results:
- Identification of key genetic variants and neurobiological differences contributing to ASD etiology.
- Establishment of a framework for targeted pharmacotherapy development, emphasizing early-stage research and testing.
- Initiation of the EU-AIMS Initiative to foster integrated, collaborative translational research in ASD.
Conclusions:
- Characterizing genotypic and phenotypic differences in ASD can enable subgroup stratification for tailored interventions.
- A structured approach, from basic research to clinical trials, is essential for developing effective ASD pharmacotherapies.
- The EU-AIMS Initiative represents a significant step towards a personalized approach to diagnosing and treating ASD through collaborative research.
Related Concept Videos
01:19Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
01:26Modeling in Therapy
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...